Deconstructing antiseizure mechanisms of anterior thalamic nucleus electrical stimulation
Active Project Grant Awarded Last action
- Award ID
- R01NS129984
- Recipient
-
Emory University UEI S352L5PJLMP8
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,085,591
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 46% complete
- Place of performance
- Atlanta, GA 30322, USA
Award details come from USAspending.gov.
Description
- Abstract
- Epilepsy is one of the most prevalent neurological disorders. Patients with epilepsy experience abnormal brain activity causing seizures or periods of unusual behavior, sensations, and often loss of awareness or consciousness. Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) is an approved therapy that effectively reduces seizures in many patients with drug resistant epilepsy, but very rarely leads to all-important complete freedom from disabling seizures. This GAP in treatment effectiveness may stem from limited understanding of the mechanism underlying ANT-DBS, as IT remains unknown not only which areas of a complex neuronal network ANT-DBS must modulate, but also how those structures are modulated, to achieve its therapeutic effect. We hypothesize that ANT-DBS results in direct, local inhibition of ANT neurons, and its downstream pathway. We propose a set of experiments to identify and modulate the neuronal network components that mediate ANT-DBS effectiveness, using the intrahippocampal kainic acid mouse model of temporal lobe epilepsy. We will first determine whether ANT neurons contribute to the seizure suppressive effect of ANT-DBS by ablating or modulating subpopulations of intrinsic neurons (AIM1). We then will examine whether the ANT-retrosplenial cortex (RSCX) pathway is a necessary conduit for ANT- DBS to be effective, by manipulating RSCX neurons that receive direct input from the ANT (aim 2). Finally, we will test the hypothesis that ANT-DBS might suppress seizure by inhibiting afferent axons from areas projecting to the ANT, such as the mammillary bodies (aim 3). Identifying the circuit mechanism of ANT-DBS would improve patient outcomes by leading to more precise guidelines for improved device targeting, prediction of patients that respond to ANT- DBS, and pave the way for novel therapies that can target this seizure-resistant network or use similar mechanisms.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $515,875 | |
| Amendment | $476,464 | |
| Amendment | $546,626 | |
| Original award | $546,626 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Rutgers, The State University | $42,566 | |
| Rutgers, The State University | $42,566 | |
| Rutgers, The State University | $42,566 |
Quick answers
Who received award R01NS129984?
R01NS129984 was awarded to Emory University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 20, 2024.
How much is award R01NS129984 worth?
$2,085,591 has been obligated on R01NS129984.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award